Replimune Group, Inc. (REPL) KPIs and segments
REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q/A on Nov 6, 2026Score 1/30
$21.78−1.50 (-6.44%)
Close on Nov 11, 2026Market cap $2.06BP/E –Yield –
KPIs & segments
Operating metrics and segments that drive Replimune's business
Coming soon
This tab will track the numbers specific to Replimune's business model — such as store count, revenue by banner, revenue per store and new openings — taken from filings and earnings releases.
See a number that looks wrong?